To use all functions of this page, please activate cookies in your browser.
My watch list
my.chemeurope.com
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
SB649868SB649868 is an orexin receptor antagonist in development by GlaxoSmithKline. Currently in Phase 2 development, this drug for sleep disorders is one of two such compounds currently in development, the other being Actelion's ACT-078573. Product highlightGSK presentation
|
| This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "SB649868". A list of authors is available in Wikipedia. |
Last viewed
- Surprising semiconductor properties revealed with innovative new method - Discovery reveals role of oxygen impurities in semiconductor properties
- Grace earns Environmental, Health and Safety Management System Certification
- Successful pilot plant for CO2 capture to start long-term test - Cooperation for CO2 scrubbing of RWE Power, BASF and Linde to be continued
- Evonik to start up large-scale production facilities in 2014 - Company to implement over €3 billion of its investment program by the end of 2014
